Department of Surgical, Oncological and Oral Sciences, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy.
Medical Oncology, Department of Pneumology and Oncology, AORN Ospedali dei Colli, Via Leonardo Bianchi, 80131 Naples, Italy.
Crit Rev Oncol Hematol. 2023 Feb;182:103899. doi: 10.1016/j.critrevonc.2022.103899. Epub 2022 Dec 31.
Liquid biopsy has gained increasing interest in the growing era of precision medicine as minimally invasive technique. Recent findings demonstrated that detecting minimal or molecular residual disease (MRD) in NSCLC is a challenging matter of debate that need multidisciplinary competencies, avoiding the overtreatment risk along with achieving a significant survival improvement. This review aims to provide practical consideration for solving data interpretation questions about MRD in NSCLC thanks to the close cooperation between biologists and oncology clinicians. We discussed with a translational approach the critical point of view from benchside, bedside and bunchside to facilitate the future applicability of liquid biopsy in this setting. Herein, we defined the clinical significance of MRD, focusing on relevant practical consideration about advantages and disadvantages, speculating on future clinical trial design and standardization of MRD technology.
液体活检作为一种微创技术，在精准医学的发展时代引起了越来越多的关注。最近的研究结果表明，检测非小细胞肺癌（NSCLC）中的微小残留病灶（MRD）是一个具有挑战性的争议问题，需要多学科的专业能力，既要避免过度治疗的风险，又要实现显著的生存改善。本综述旨在通过生物学家和肿瘤临床医生的密切合作，为解决 NSCLC 中 MRD 数据解释问题提供实用的考虑因素。我们采用转化研究的方法，从实验室、病床和临床实践等方面讨论了关键的观点，以促进液体活检在这一领域的未来应用。在这里，我们定义了 MRD 的临床意义，重点讨论了相关的实际考虑因素，包括优缺点，推测未来临床试验设计和 MRD 技术的标准化。
